Study of Adze1.C for advanced melanoma
Part of Cancer, Skin clinical trials.
This trial tests a new injected virus therapy (Adze1.C) for people with advanced melanoma that hasn't responded to other treatments. The virus is designed to attack tumors directly and may help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have advanced melanoma (Stage IIIB or IV) that cannot be removed by surgery and has not responded to standard treatments.
- You have at least one tumor or lymph node that can be directly injected with the study drug.
- You must be in good general health (ECOG score 0 or 1).
- You cannot have had other oncolytic virus treatments in the last 2 months or any adenovirus treatment before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This trial tests a new virus-based treatment for advanced melanoma that has spread to the brain or other parts of the body. The virus is injected directly into a tumor to try to kill it, and it may boost your immune system against the cancer.
This Phase 2 study tests crizanlizumab alone or with nivolumab to treat people with certain brain tumors that have spread to the brain (melanoma) or glioblastoma. The goal is to see whether this approach can control the disease and improve outcomes.
This trial tests a new treatment, T3011, which is a virus that targets and kills cancer cells while also boosting your immune system. It's for people with advanced melanoma, and the goal is to see if it can shrink tumors and help you live longer.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.